Does Incretin Agonism Have Sustainable Efficacy?

Area of Science:

• Endocrinology and Metabolism
• Pharmacology of metabolic diseases
• Gastroenterology

Background:

• Obesity is a major health concern linked to numerous complications.
• Incretin hormones (GLP-1 and GIP) play a crucial role in glucose homeostasis and are secreted after nutrient ingestion.
• The 'incretin effect' highlights the significance of gut hormones in regulating insulin secretion and glucose metabolism.

Purpose of the Study:

• To review the mechanism of action, benefits, and challenges of synthetic incretin (GLP-1 and GIP) receptor agonists.
• To discuss the potential long-term sustainability and safety of these incretin-based therapies.
• To briefly examine other molecules involved in glucose homeostasis, such as amylin and glucagon.

Main Methods:

• Review of recent clinical trials and randomized studies on GLP-1 and GIP receptor agonists.
• Analysis of the physiological roles of incretins, amylin, and glucagon in glucose metabolism and energy balance.
• Discussion of potential adverse effects and long-term outcomes based on current evidence and theoretical considerations.

Main Results:

• Synthetic GLP-1 and GIP agonists demonstrate significant efficacy in improving glycemic control and promoting weight loss.
• These agonists have shown promise in preventing obesity-related complications, including type 2 diabetes, cardiovascular events, and renal issues.
• Observed benefits persist even in patients concurrently treated with metformin or insulin.

Conclusions:

• Incretin agonists offer substantial benefits for obesity and related metabolic disorders, with proven efficacy in clinical trials.
• The long-term sustainability of incretin agonism is questionable due to potential pancreatic beta-cell exhaustion and unknown effects on the neurohormonal axis.
• Further research is essential to ascertain the long-term safety and efficacy of these agents, alongside the development of novel therapeutic combinations.